Literature DB >> 2043775

Interleukin-6 is a prognostic factor in multiple myeloma.

H Ludwig, D M Nachbaur, E Fritz, M Krainer, H Huber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2043775

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  29 in total

Review 1.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 3.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.

Authors:  E Shannon; F Sandoval; N Greig; P Stagg
Journal:  Int Immunopharmacol       Date:  2012-01-11       Impact factor: 4.932

5.  Cytokines involved in the progression of multiple myeloma.

Authors:  F Merico; L Bergui; M G Gregoretti; P Ghia; G Aimo; I J Lindley; F Caligaris-Cappio
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 6.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

Review 7.  Current drug therapy for multiple myeloma.

Authors:  Y W Huang; A Hamilton; O J Arnuk; P Chaftari; R Chemaly
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

8.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

10.  The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development.

Authors:  Wai W Lin; Zuoan Yi; Laura L Stunz; Christian J Maine; Linda A Sherman; Gail A Bishop
Journal:  Sci Signal       Date:  2015-09-01       Impact factor: 8.192
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.